Tevogen Receives $1 Million to Accelerate AI Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Funding Rounds

▤ Summary

Tevogen received $1 million as part of a previously announced nondilutive funding agreement with KRHP LLC. The company will use the money to accelerate Tevogen.AI, its AI-powered drug discovery and development program. Tevogen says the funding will help improve target discovery, shorten development timelines, and support treatments for cancer and infectious diseases. The company also says it remains well capitalized and has access to a $36 million line of credit to support its growth strategy.

$ Funding

$
Amount $1.0M Total raised
□
Date August 7, 2025 Announcement date
◎
Investors - Lead investors
▥
Company Tevogen.com Funded company

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies